CuriRx
CuriRx is a minority woman-owned Contract Research, Development, and Manufacturing Organization (CRDMO) based in Massachusetts. The company provides comprehensive solutions for drug development with expertise in bioprocessing, formulation development, analytical testing, and manufacturing support. CuriRx offers services across the therapeutic development spectrum, including customized solutions, collaboration, cutting-edge analytical methods, and process optimization to accelerate client projects from discovery to clinical and commercial stages.
Industries
N/A
CuriRx
205 Lowell Street, Suite 1C, Wilmington, MA 01887
Patents
Services
Method development, qualification, validation; non-GMP and GMP testing, stability studies, release testing, CMC characterization with advanced instrumentation.
Preformulation and formulation for diverse dosage forms, injectables, ocular, oral, and topical products, including high-concentration solutions and delivery systems.
Cell line/clone selection, upstream and downstream process development and optimization, including fermentation and purification.
Customized lyophilization development to improve the stability and shelf-life of complex injectables with scale-up and transfer capabilities.
Method development, qualification, validation; non-GMP and GMP testing, stability studies, release testing, CMC characterization with advanced instrumentation.
Preformulation and formulation for diverse dosage forms, injectables, ocular, oral, and topical products, including high-concentration solutions and delivery systems.
Cell line/clone selection, upstream and downstream process development and optimization, including fermentation and purification.
Customized lyophilization development to improve the stability and shelf-life of complex injectables with scale-up and transfer capabilities.
Expertise Areas
- Formulation development
- Bioprocessing
- Analytical testing and characterization
- Lyophilization
Key Technologies
- High-resolution mass spectrometry
- Size exclusion chromatography (SEC-HPLC)
- Orthogonal analytical methods
- Chromatographic separation techniques
Key People
Scientific Advisor
Director, Formulation Development
Senior Manager of HR Operations, Culture & Engagement
Senior Quality Manager
Scientific Advisor
Director, Formulation Development
Senior Manager of HR Operations, Culture & Engagement
Senior Quality Manager
News & Updates
Awarded a multi-year contract from the NCI for development and production of parenteral cancer drugs for clinical studies.
Describes analytical approaches for formulation and characterization of multiple high-concentration monoclonal antibodies for subcutaneous delivery.
Describes enhanced HPLC methods to improve protein and peptide aggregate quantification in biotherapeutics.
Announced participation in the 2023 Bioprocessing International Conference, a platform for showcasing capabilities and engaging with industry peers.
Launched a center integrating state-of-the-art bioprocessing laboratories and high-resolution analytical instrumentation for end-to-end drug development support.
Introduced a new platform to provide CMC analytical services using high-resolution mass spectrometry for complex biotherapeutic product development.
Awarded a multi-year contract from the NCI for development and production of parenteral cancer drugs for clinical studies.
Describes analytical approaches for formulation and characterization of multiple high-concentration monoclonal antibodies for subcutaneous delivery.
Describes enhanced HPLC methods to improve protein and peptide aggregate quantification in biotherapeutics.
Announced participation in the 2023 Bioprocessing International Conference, a platform for showcasing capabilities and engaging with industry peers.
Launched a center integrating state-of-the-art bioprocessing laboratories and high-resolution analytical instrumentation for end-to-end drug development support.
Introduced a new platform to provide CMC analytical services using high-resolution mass spectrometry for complex biotherapeutic product development.